Hydrazide containing nuclear transport modulators and uses thereof
View Patent ↗The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
1. A method of treating cancer in a veterinary subject in need thereof comprising administering to the subject a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof,
wherein the cancer is breast cancer, lymphoma, leukemia, or myeloma.
2. The method according to claim 1 , wherein treating comprises dosing every 4-120 hours.
3. The method according to claim 1 , wherein treating comprises dosing from about 0.5 mg/kg to about 100 mg/kg of body weight of the veterinary subject.
4. The method according to claim 3 , wherein the dosing is 5 mg/kg of body weight of the veterinary subject.
5. The method according to claim 3 , wherein the dosing is 10 mg/kg of body weight of the veterinary subject.
6. The method according to any one of claims 1 - 5 , wherein the veterinary subject is a dog.
7. The method according to any one of claims 1 - 5 , wherein the cancer is lymphoma.
8. The method according to any one of claim 1 or 3 - 5 , wherein treating comprises a single dose followed by a maintenance dose.
9. The method according to any one of claims 1 - 5 , wherein treating comprises oral, intravenous, intraperitoneal, intramuscular or intradermal administration.
10. The method of any one of claims 1 - 5 , wherein the cancer is breast cancer.
11. The method of any one of claims 1 - 5 , wherein the cancer is leukemia.
12. The method of any one of claims 1 - 5 , wherein the cancer is myeloma.